Cosmos Health: A Company Transformed — 2026 Year-to-Date
Record Revenue Across All Quarters Reported. Balance Sheet Deleveraged. Capital Structure Streamlined. Proprietary IP Filed in Four Global Markets. U.S. Market Entered. Global rollout of proprietary brands continues. Share repurchases underway. Reaffirms Guidance Targets
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026
- Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M. Full-year 2026 guidance: $90M+.
- ATW $8M convertible note retired 12 months early, eliminating further conversions and dilution.
- Strengthened balance sheet: H1 2026 total liabilities reduced 13.3% and stockholders’ equity increased 12.2%.
- Simplified capital structure: No shelf registration, no ATM and no floorless warrants.
- 5.1M+ shares repurchased for approximately $1.11M under the $5M buyback authorization.
- Management increasing ownership: CEO Greg Siokas personally increased ownership by 3.3M+ shares in 2025 and a further 7.8M+ shares in 2026, bringing his total holding to 14.6M shares.
- Zacks Small-Cap Research initiates coverage with a $4.50 price target versus a share price well below that level.
- C-Scrub now in Tesco and Superdrug, alongside expansion into hospital, surgical and animal health channels.
- Sky Premium Life global rollout includes Saudi Arabia, Qatar, the UAE and pan-European availability across all 27 EU Member States.
- CCX0722 hydrogel patent WO2025108566A1 filed in the U.S., Europe, Australia and Canada.
- 18 Series U.S. buildout: Cur18™, Liv18™, Oliv18™ and Fort18™ launched or in production. NOOR Collagen DTC has achieved a >60% repeat rate. Combined projected U.S. revenue exceeds $22.7M at 70%+ gross margins.
- $3.1M invested in BTC + ETH, with Bitcoin holdings now in a gain position.
- Approximately $20M in non-core assets identified for potential monetization, including wholly owned real estate and digital assets.
- Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies and cost reduction initiatives.
- 2029 guidance reaffirmed: $200.6M revenue, $71.2M gross profit, $31.0M net income and $44.2M adjusted EBITDA.
CHICAGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (NASDAQ: COSM) (“Cosmos Health” or the “Company”) today presents a comprehensive corporate update covering all significant operational, financial and strategic milestones from January 1, 2026 through August 31, 2026.
The Company has executed across every dimension of its stated strategy in 2026: record revenue in every reporting period, a deleveraged and simplified balance sheet, a growing proprietary IP portfolio, meaningful U.S. brand launches, accelerating international expansion, AI-led operational upgrades and active share repurchases. The update below is structured to give investors a complete view of that transformation.
I. Financial Performance: Three Consecutive Record Periods
Cosmos Health has delivered its highest revenue in Company history across every reporting period in 2026, building on a record FY2025.
FY2025: Revenue reached $65.27M, up 20% year over year, representing the strongest annual result in Company history. Gross profit surged 83% to $7.9M, gross margin expanded 418 basis points, adjusted EPS improved 82% and cash rose more than tenfold to $3.5M. Every core segment contributed, with CosmoFarm expanding its pharmacy network, Cana scaling contract manufacturing under long-term agreements, Decahedron growing UK distribution and Sky Premium Life expanding globally.
Q1 2026: Revenue reached $17.93M, up 30.7%, setting a record for the first quarter. Total liabilities declined $4.5M, or 9.6%, while stockholders’ equity increased 7.6%. The liabilities-to-assets ratio improved to 68.2% from 71.9% at year-end 2025, while adjusted EBITDA approached breakeven. Commercial momentum included more than 75 pharmacies added at CosmoFarm, continued Sky Premium Life growth across multiple markets and an expanded Cana orderbook.
Q2 2026: Revenue reached $18.99M, up 28.8%, setting another quarterly record, while H1 2026 revenue reached $36.91M, up 29.7%. Adjusted gross profit increased 58% year over year, total liabilities declined $6.27M, stockholders’ equity increased 12.2% and the liabilities-to-assets ratio improved by 550 basis points. The annualized adjusted revenue run-rate exceeded $75M.
Every core division contributed during the quarter. CosmoFarm added more than 75 pharmacies, Cana's orderbook reached an all-time high of more than 25 million units and Decahedron nearly doubled its UK revenue.
Operating Efficiency: Operating cash requirements in H1 2026 ran more than 30% below the average of the prior two years, reflecting revenue growth, operating efficiencies and disciplined cost control. Management views this as a meaningful step toward the Company's 2027 profitability targets.
| METRIC | FY2025 | Q1 2026 | Q2 2026 | H1 2026 |
|---|---|---|---|---|
| Revenue | $65.27M (+20%) | $17.93M (+31%) | $18.99M (+28.8%) | $36.91M (+29.7%) |
| Adj. Gross Profit | $7.9M (+83%) | $1.85M | +58% YoY | Expanding |
| Total Liabilities | Improved | −$4.5M (−9.6%) | −$6.27M (−13.3%) | 550bps improvement |
| Stockholders’ Equity | Improved | +7.6% | +12.2% / Consistent growth | |
| Adj. EBITDA | Improving | −$229K (near breakeven) | −$1.13M (improved) | Trend up |
II. Strengthened Balance Sheet and Capital Structure
The most consequential financial development of 2026 is the transformation of Cosmos Health's capital structure. The Company has methodically removed meaningful dilution-overhang mechanisms and, as a result, expects its share count to remain broadly stable under its existing capital structure before accounting for reductions from ongoing share repurchases.
Convertible note repaid: On August 28, 2026, the Company repaid in full its $8.0 million senior secured convertible note issued to ATW, together with all accrued interest, twelve months ahead of its August 2027 maturity. The repayment eliminates any further conversions or dilution from that instrument.
Shelf registration withdrawn: The Company has withdrawn its Form S-1 and Form S-3 registration statements. No effective shelf registration or ATM offering program is currently in place.
No structured or floorless warrants: Remaining warrants carry fixed exercise prices with no reset or ratchet provisions. In May 2026, 4,874,126 Series B warrants expired unexercised, with no new shares issued, removing approximately 38% of the total warrant overhang. The next tranche carries an exercise price of $0.95 per share.
Share repurchase program: The Company has repurchased 5,112,000 shares for approximately $1.11 million under its $5.0 million authorization, with open-market purchases continuing.
Non-core assets: Approximately $20 million in non-core assets have been identified for potential monetization, including real estate, digital assets and marketable securities. This includes approximately $15 million in real estate at fair market value and $3.1 million invested in digital assets comprising Bitcoin and Ethereum.
| DECEMBER 31, 2025 | JUNE 30, 2026 | CHANGE | |
|---|---|---|---|
| Total liabilities | $47.05M | $40.79M | −$6.27M / −13.3% |
| Stockholders’ equity | $18.42M | $20.67M | +$2.25M / +12.2% |
| Liabilities-to-assets ratio | 71.9% | 66.4% | 550 basis points improvement |
III. Diversified Asset Base and Digital Assets Strategy
The Company maintains a diversified asset base spanning liquid assets, digital holdings and real estate, alongside access to non-dilutive financing. Together, these resources provide flexibility to fund the Company's next phase of growth without recourse to equity issuance.
As previously stated, the Company has identified approximately $20 million in non-core assets for potential monetization that could be converted to liquidity without impacting core operations. These primarily comprise digital assets, in which more than $3 million has been invested to date, and a real estate portfolio with a fair market value of approximately $15 million.
Digital Assets
Cosmos Health has built a disciplined digital asset program as a component of its treasury strategy, with an initial focus on Ethereum followed by strategic expansion into Bitcoin:
- February 2026: $500K Bitcoin purchase, taking total investments in digital holdings to $2.5M.
- March 2026: $600K Bitcoin purchase, taking total investments in digital holdings to $3.1M.
- August 2026: Bitcoin holdings were in a gain position as of the date of the applicable release and available for opportunistic monetization.
Real Estate
Beyond its liquid and digital assets, Cosmos Health owns a real estate portfolio with an independent fair market valuation of approximately $15 million.
The portfolio includes Cana Laboratories' manufacturing facility in Athens, situated on a land plot of approximately 54,000 square feet, and the CosmoFarm logistics center in western Athens, measuring approximately 29,100 square feet. Both properties are wholly owned by the Company.
European Investment Bank Financing
In May 2026, Cana Laboratories entered into an advisory agreement with the European Investment Bank (EIB) for the financing of a €50 million R&D program.
Under the arrangement, EIB financing could represent up to 50%, or €25 million, through the EIB's Venture Debt Program. This sits alongside available credit facilities and other non-dilutive financing sources that may be explored.
IV. Analyst Coverage and Valuation
On January 14, 2026, Zacks Small-Cap Research initiated analyst coverage of Cosmos Health with a $4.50 price target, representing a significant premium to where the stock has traded.
The initiation cited the Company's revenue trajectory, brand portfolio and proprietary pipeline as key drivers. Analyst estimates and price targets represent the views of the issuing firm and not those of the Company.
V. Divisional Performance Snapshot
| DIVISION | 2026 KPI | KEY MILESTONES |
|---|---|---|
| CosmoFarm | >$15M / Q2 | Record Q2; $60M+ annualized run-rate. 80+ pharmacies added. AI robotic automation and inventory management deployed. LOI signed to acquire $11.5M pharmacy distribution network. |
| Cana Laboratories | 25M+ unit orderbook | All-time high contract manufacturing backlog; multi-year agreements up to 10 years. >$10M projected recurring annual profit. Verisfield: 3.9M-unit agreement. Pharmex: 2.86M-unit agreement. Provident: 385K units. EU GMP-certified. |
| Decahedron (UK) | Near 2× revenue | Nearly doubled revenue YoY in Q2 2026. Key distribution hub for UK and European markets with continued growth momentum. |
| 18 Series / NOOR | $22.7M+ projected | Cur18™, Liv18™, Oliv18™ and Fort18™ launched or in production. NOOR Collagen >60% repeat rate and >50% margins. U.S. subscription model live. |
| Sky Premium Life | 5M+ units / Saudi | Saudi Arabia exclusive five-year deal; Qatar agreement; third consecutive UAE order; availability across all 27 EU Member States; continued expansion in Albania and the UK. |
| C-Scrub / C-Sept | UK + hospital + animal health | C-Scrub live at Tesco and Superdrug. EN 12791 certification for surgical hand disinfection. C-Sept PRO gaining traction in Greek hospital groups. Veterinary C-Scrub launched. |
| CCX0722 Hydrogel | 4 patent markets | WO2025108566A1 advanced into the U.S., EU, Australia and Canada. Mechanical satiety platform swelling more than 100-fold with no systemic absorption. Owned outright by Cana. |
VI. UK Retail Breakthrough, New Channels and Growth Initiatives
In February 2026, Cosmos Health achieved a landmark dual placement for C-Scrub in the United Kingdom, securing listings with two of the country's largest retailers.
Tesco: The UK's largest retailer, holding approximately 30% market share and generating more than $80 billion in annual global revenue, serving tens of millions of customers weekly.
Superdrug: The UK's second-largest beauty and health retailer, operating more than 830 stores, including 200+ in-store pharmacies across the UK and Republic of Ireland, alongside a substantial e-commerce platform.
Placement with both retailers significantly expands C-Scrub's UK visibility and establishes a platform for the potential rollout of additional Cosmos Health products.
The Company has subsequently expanded the franchise into additional channels.
Hospital and surgical: In April 2026, C-Scrub Wash 4% completed testing under EN 12791, the European standard for surgical hand disinfection, supporting entry into hospital, surgical and professional healthcare procurement channels. C-Sept PRO has since gained traction across leading Greek public and private hospital groups.
EU expansion: C-Scrub and C-Sept reported annualized sales above $1.5 million at gross margins exceeding 70%, with planned European expansion targeting $2.5 million in 2026 revenue and $7.4 million in revenue with $5.3 million in gross profit by 2028.
Animal health: In June 2026, Veterinary C-Scrub Wash 4% was certified under EN 1656 and EN 1657 European standards, opening access to the $69 billion global animal health market. The veterinary line extends an existing certified formulation manufactured internally at Cana's facility.
Acquisitions
The Company is actively exploring acquisitions that could be immediately accretive and accelerate progress toward its stated guidance targets. Two letters of intent have been signed to date.
Pharmacy distribution network: In March 2026, Cosmos Health signed an LOI to acquire an $11.5 million pharmacy distribution network, further expanding CosmoFarm's reach.
Doc Pharma S.A.: In June 2026, the Company signed an LOI to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer expected to expand assets, production capacity, product portfolio and profitability.
VII. International Expansion: Saudi Arabia, Dubai and Global Markets
Cosmos Health accelerated the international rollout of its proprietary brands during 2026, adding exclusive and long-term distribution partnerships across the Gulf while achieving full European coverage for Sky Premium Life.
Saudi Arabia: In August 2026, Cosmos Health entered the Kingdom through an exclusive five-year distribution agreement with Innova Healthcare, one of Saudi Arabia's largest retail pharmacy networks. The agreement covers the full Sky Premium Life range.
An initial purchase order of 126,000 units was secured upon execution, with total expected volume exceeding 5 million units over the initial five-year term. Innova also holds a first right of refusal on new Cosmos Health products developed or acquired during the term.
Qatar: In June 2026, the Company signed a distribution agreement with International Medical Company, whose Kulud Pharmacies retail arm operates more than 130 branches, securing an initial order of 31,000 Sky Premium Life units.
United Arab Emirates: In April 2026, a third consecutive purchase order was received from Pharmalink for 60,000 Sky Premium Life units, taking cumulative orders to 270,000 units against a five-year goal exceeding 3 million units.
European Union: In June 2026, Sky Premium Life achieved pan-European distribution through Skroutz, making 96 products available across all 27 EU Member States.
Albania: In July 2026, the Pharma Cell partnership scaled to more than 4,500 monthly units, with annualized orders projected to exceed 54,000 units.
Dubai: In February 2026, Cosmos Health showcased its expanding brand portfolio at the World Health Expo Dubai 2026, reinforcing the Company's presence across the Middle East and MENA region.
VIII. CCX0722 Hydrogel: International Patent in Four Markets
On June 25, 2026, Cana Laboratories advanced international patent application WO2025108566A1, “Hydrogel for Body Weight Management,” into the European regional phase and national phases in the United States, Australia and Canada.
The IP was acquired outright from Cloudpharm on June 8, 2026, giving Cana full ownership with no licensing fees, royalty sharing or third-party IP dependency.
CCX0722 operates through a mechanical mechanism with no systemic absorption. Taken as a capsule before meals, the dried hydrogel absorbs water in the stomach and swells more than 100-fold into soft gel pieces that occupy stomach volume to support satiety before naturally passing through the gastrointestinal tract.
The global weight-management market was valued at $190.6 billion in 2025 and is projected to reach $562.2 billion by 2033, representing a 14.2% compound annual growth rate.
IX. U.S. Proprietary Brand Buildout: The 18 Series Platform
The 18 Series is Cosmos Health's portfolio of science-validated nutraceutical products manufactured in the United States at facilities holding GMP certification and FDA registration.
Cur18™ is a patented, clinically studied curcumin formulation delivering up to 39× higher free curcumin bioavailability compared with standard 95% curcuminoid extracts. Its U.S. commercial launch began in Q2 2026.
Liv18™ is a clinically validated liver-health supplement. Phase 1 has been completed and production commenced in April 2026 at a GMP-certified, FDA-registered and UL-audited U.S. facility. The product is projected to generate more than $5 million in annual revenue at approximately 75% gross margin.
Oliv18™ is a whole-olive polyphenol product carrying USDA and EU organic certification and utilizing a 100% solvent-free formulation. It targets U.S. cardiovascular and antioxidant categories and is projected to generate more than $6 million in annual revenue at approximately 72% gross margin within 12–18 months.
Fort18™, a men's wellness supplement introduced in May 2026, is projected to contribute more than $3.2 million in incremental annual U.S. revenue within 12–18 months.
NOOR Collagen, a Korean-developed premium collagen product, has launched through a subscription model with an early repeat purchase rate exceeding 60% and gross margins above 50%. It is projected to generate more than $12 million in annualized revenue.
Combined, the 18 Series and NOOR U.S. portfolio projects more than $22.7 million in annualized revenue and approximately $17.0 million in gross profit, creating a structurally high-margin, direct-to-consumer and subscription-capable platform.
X. AI Strategy and Operational Infrastructure
AI has moved from strategy to execution at Cosmos Health in 2026, with deployments spanning commercial, logistics and research functions.
Enterprise integration: In April 2026, AI was deployed across front-end order and customer management, back-end warehouse, inventory and supply-chain operations, and the proprietary Cloudscreen drug-repurposing platform. The Company believes these systems have the potential to reduce certain operating expenses by up to 30%.
CosmoFarm automation: AI robotic automation has been deployed for inventory management and order fulfillment, alongside expanded facility capacity capable of supporting an additional $40 million+ in annual revenue.
Customer operations: In June 2026, the Company signed an agreement for an AI-powered call center offering multilingual voice capabilities, outbound campaigns and real-time reporting to optimize order intake and customer communications.
Subscription platform: In July 2026, Cosmos Health announced development of an AI-enabled digital subscription platform spanning consumer and corporate channels, building on the U.S. launch of NOOR Collagen and its early repeat purchase rate above 60%.
These investments underpin the operating leverage the Company expects to demonstrate as revenue scales toward $90 million and beyond.
XI. 2026–2029 Financial Guidance Reaffirmed
The Company reaffirms its financial guidance issued May 26, 2026. Management states that H1 2026 performance remains consistent with the trajectory required to achieve these targets.
| METRIC | FY2025 (ACTUAL) | 2026 (GUIDANCE) | 2027 (GUIDANCE) | 2029 (GUIDANCE) |
|---|---|---|---|---|
| Revenue | $65.3M | >$90M (+38%) | $130.7M | $200.6M |
| Gross Profit | $7.9M (12.1%) | Expanding | $36.7M | $71.2M (35.5%) |
| Net Income | Loss | Near B/E path | $8.7M | $31.0M |
| Adj. EBITDA | Improving | Improving | $16.5M | $44.2M |
| Cash | $3.5M | Stable+ | $17.3M | $62.9M |
The expected 32% CAGR is projected to be driven by a structural margin shift toward proprietary segments, including the 18 Series with 72–75% gross margins, CCX0722 licensing or co-development and Cana contract manufacturing, alongside continued organic growth in distribution.
Management believes achieving these targets would create significant value for shareholders as the Company transitions toward a self-funded model supported by stronger cash flows.
XII. Complete 2026 Milestone Timeline
| DATE | MILESTONE |
|---|---|
| Jan 14 | Zacks Small-Cap Research initiates analyst coverage with $4.50 price target |
| Jan 20 | Accelerating CosmoFarm customer growth; robotic expansion supporting $40M+ additional annual revenue |
| Feb 11 | $500K Bitcoin purchase — digital asset program expanded to $2.5M total |
| Feb 17 | Cosmos Health showcases expanding brand portfolio at World Health Expo Dubai 2026 |
| Feb 18 | C-Scrub listed at Tesco, the UK's largest retailer |
| Feb 18 | C-Scrub listed at Superdrug, the UK's second-largest beauty and health retailer |
| Feb 19 | Company highlights approximately $15M fair market value of real estate assets |
| Mar 10 | $600K Bitcoin purchase — total digital asset holdings reach $3.1M |
| Mar 11 | LOI signed to acquire $11.5M pharmacy distribution network |
| Mar 19 | Corporate update: NOOR Collagen projected at $12M+ annualized revenue |
| Apr 1 | C-Scrub Wash 4% completes EN 12791 testing for surgical hand disinfection |
| Apr 8 | Planned U.S. launch of Liv18™ announced |
| Apr 13 | Third consecutive Pharmalink purchase order — 60,000 Sky Premium Life units for the UAE |
| Apr 15 | FY2025 results: Record $65.27M revenue (+20%), gross profit +83%, gross margin +418bps and cash above $3.5M |
| Apr 16 | Enterprise AI integration announced — potential to reduce certain operating expenses by up to 30% |
| Apr 17 | Cur18™ U.S. commercial launch announced for Q2 2026 |
| Apr 20 | Liv18™ Phase 1 complete; production commencing — $5M+ projected revenue at approximately 75% gross margin |
| Apr 30 | Cur18™ projected to contribute $2.5M+ in incremental annual U.S. revenue |
| May 6 | Fort18™ introduced, extending the 18 Series into men's wellness |
| May 11 | Fort18™ projected to contribute $3.2M+ in incremental annual U.S. revenue |
| May 12 | Registration Statement on Form S-1 withdrawn |
| May 14 | Advisory agreement signed with the European Investment Bank for a €50M R&D program, with financing potential up to €25M |
| May 21 | Q1 2026 results: Record $17.93M (+31%); liabilities −$4.5M; equity +7.6%; adjusted EBITDA near breakeven |
| May 21 | 4,874,126 Series B warrants expire unexercised — approximately 38% of warrant overhang removed with no dilution |
| May 26 | 2026–2029 financial guidance: $90M+ in 2026 and $200.6M by 2029 |
| Jun 1 | Veterinary C-Scrub Wash 4% launched — entry into the $69B global animal health market |
| Jun 4 | Pan-European distribution achieved for Sky Premium Life across all 27 EU Member States via Skroutz |
| Jun 4 | Approximately $20M in non-core assets identified for potential monetization |
| Jun 5 | Oliv18™ launched in the United States |
| Jun 8 | Cana Laboratories acquires CCX0722 patent application from Cloudpharm — full IP ownership consolidated |
| Jun 9 | New capsule production line inaugurated; five-year Provident agreement for 385,000 units of CERTORUN |
| Jun 10 | Three-year, 3.9M-unit contract manufacturing agreement signed with Verisfield |
| Jun 11 | LOI signed to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer |
| Jun 12 | C-Scrub and C-Sept annualized sales exceed $1.5M at 70%+ gross margins |
| Jun 12 | Contract manufacturing orders totaling 253,657 units received from Nassington and Verisfield |
| Jun 15 | U.S. portfolio update: four 18 Series products with $22.7M+ projected annualized revenue at approximately $17M gross profit |
| Jun 17 | Pharmex S.A. contract manufacturing agreement: 2.86M units across three dermatological products |
| Jun 17 | Entry into the $163B global skincare market — Korean collagen brand already live in the U.S. |
| Jun 18 | CosmoFarm delivers record Q2 revenue above $15M; $60M+ annualized run-rate; 80+ pharmacies added |
| Jun 22 | Cana orderbook reaches all-time high of 25M+ units; >$10M recurring annual profit projected |
| Jun 23 | AI-powered call center agreement signed for CosmoFarm customer communications |
| Jun 24 | C-Sept PRO gains traction across Greek hospital groups — $1.3M+ annualized at approximately 72% gross margin |
| Jun 25 | International patent application WO2025108566A1 advanced into the U.S., EU, Australia and Canada |
| Jun 26 | Distribution agreement signed with International Medical Company for Qatar — 31,000-unit initial order |
| Jun 30 | Board authorizes $5.0M share repurchase program |
| Jul 7 | Preliminary Q2 record revenue of approximately $19.4M; 3.64M shares repurchased under $5M buyback |
| Jul 10 | Subscription model launched with NOOR Collagen — >60% repeat purchase rate and >50% gross margins |
| Jul 13 | Agreement signed with Libytec to commercialize DIABIT-IS X in Greece |
| Jul 17 | Buyback reaches 5.11M shares repurchased for approximately $1.11M; open-market purchases ongoing |
| Jul 20 | Albania expansion: Pharma Cell partnership scaled to 4,500+ monthly units and 54K+ annually |
| Jul 27 | AI-enabled digital subscription platform announced across B2C and B2B channels |
| Aug 19 | Q2 2026 results confirmed: $18.99M (+28.8%); H1 $36.91M (+29.7%); adjusted gross profit +58% |
| Aug 20 | Saudi Arabia entry: exclusive five-year agreement with Innova Healthcare; 126K initial PO; 5M+ units projected |
| Aug 24 | Oliv18™ projected to generate $6M+ annual U.S. revenue at approximately 72% gross margin within 12–18 months |
| Aug 28 | $8M ATW convertible note retired 12 months ahead of maturity; no further dilution from the instrument |
Management Commentary
Greg Siokas, CEO of Cosmos Health, stated:
"This is a different company than it was twelve months ago. We have retired $8 million of debt a full year early. We repurchased more than five million shares. We delivered record revenue in every reporting period. We placed C-Scrub in Tesco and Superdrug. We entered Saudi Arabia with a five-year exclusive distribution agreement. We filed our hydrogel patent across four global markets. We launched proprietary U.S. brands. And we did all of this while cutting our cash burn by more than 30%.
"Every pillar of our strategy is delivering. CosmoFarm is growing its pharmacy network and deploying AI. Cana has its biggest contract manufacturing orderbook in history. Decahedron nearly doubled its UK revenue. Our proprietary brands are gaining real commercial traction.
"We enter the second half of 2026 with a solid balance sheet and a streamlined capital structure, growing revenue across every division, and a clear path to $200 million in revenue and significant profitability by 2029. Cosmos is not a promise. It is performance."
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group.
The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.
Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices within the European Union.
Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK.
Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes and cancer, enhanced by artificial intelligence drug-repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics and innovative OTC products.
Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA.
With a global distribution platform, the Company is currently expanding throughout Europe, Asia and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and Harlow, UK.
More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co and www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words.
These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to:
- The Company's ability to raise sufficient financing to implement its business plan
- The effectiveness of its digital asset strategies, including accumulation and yield-generating activities
- The impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations and the economy in general
- The Company's ability to successfully develop and commercialize its proprietary products and technologies
- Changes in interest rates
- Changes in foreign currency exchange rates, commodity prices or other price inflation and deflation
- The Company's ability to issue debt on terms and at rates acceptable to it
- The impact and expected outcome of investigations, inquiries, claims and litigation
- The challenges of operating in international markets
- The adequacy of insurance coverage
- The effect of accounting charges and the adoption of certain accounting standards
- The impact of legal and regulatory changes, including changes to tax laws and regulations
- Guidance for fiscal 2026 and beyond and the Company's financial outlook
Forward-looking statements are based on currently available information and the Company's current assumptions, expectations and projections about future events.
Readers should not rely on forward-looking statements as guarantees of future performance. These statements are subject to future events, risks and uncertainties, many of which are beyond the Company's control, dependent on the actions of third parties or currently unknown, as well as potentially inaccurate assumptions that could cause actual results to differ materially from historical experience, expectations and projections.
These risks and uncertainties include, but are not limited to, those described from time to time in the Company's periodic reports filed with the U.S. Securities and Exchange Commission (SEC) and available through the SEC's website at www.sec.gov.
There also may be other factors the Company cannot anticipate or that are not described herein, generally because it does not currently perceive them to be material. Such factors could cause results to differ materially from expectations.
Forward-looking statements speak only as of the date they are made, and the Company does not undertake to update these statements other than as required by law.
Readers are advised to review any further disclosures the Company makes on related subjects in its filings with the Securities and Exchange Commission and in its other public statements.
Investor Relations Contact
BDG Communications
Email: cosm@bdgcommunications.com
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/b3c3061f-2b75-4eaf-9ca4-2e98bdd664b2